Interleukin-17A Antagonist [EPC] - N0000191495

Pharmacologic Code	N0000191495
Pharmacologic Name	Interleukin-17A Antagonist
Pharmacologic Uses	humanized interleukin-17A antagonist interleukin-17A antagonist
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

The table contains 8 products whose active ingredient are classified under the same pharmacologic class Interleukin-17A Antagonist [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0002-1445	Taltz	Non-Proprietary Name: Ixekizumab	Injection, Solution	Subcutaneous	Eli Lilly And Company	ACTIVE
	0002-7724	Taltz	Non-Proprietary Name: Ixekizumab	Injection, Solution	Subcutaneous	Eli Lilly And Company	ACTIVE
	0002-8900	Taltz	Non-Proprietary Name: Ixekizumab	Injection, Solution	Subcutaneous	Eli Lilly And Company	ACTIVE
	0002-8905	Taltz	Non-Proprietary Name: Ixekizumab	Injection, Solution	Subcutaneous	Eli Lilly And Company	ACTIVE
	0078-0639	Cosentyx	Non-Proprietary Name: Secukinumab	Injection	Subcutaneous	Novartis Pharmaceuticals Corporation	ACTIVE
	0078-1056	Cosentyx	Non-Proprietary Name: Secukinumab	Injection	Subcutaneous	Novartis Pharmaceuticals Corporation	ACTIVE
	0078-1070	Cosentyx	Non-Proprietary Name: Secukinumab	Injection	Subcutaneous	Novartis Pharmaceuticals Corporation	ACTIVE
	0078-1168	Cosentyx	Non-Proprietary Name: Secukinumab	Injection, Solution, Concentrate	Intravenous	Novartis Pharmaceuticals Corporation	ACTIVE